{{chembox
| Verifiedfields = changed
| verifiedrevid = 461099359
| ImageFile=felypressin.png
| ImageSize=
| IUPACName=<small>1-[19-Amino-13,16-dibenzyl-10-(2-carbamoyl-ethyl)-7-carbamoylmethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloeicosane-4-carbonyl]-pyrrolidine-2-carboxylic acid [5-amino-1-(carbamoylmethyl-carbamoyl)-pentyl]-amide</small>
| OtherNames=
|Section1={{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16736539
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1697764
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 17N2918V6G
| InChI = 1/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
| InChIKey = SFKQVVDKFKYTNA-DZCXQCEKBI
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SFKQVVDKFKYTNA-DZCXQCEKSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo=56-59-7
| PubChem=5956
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00093
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 60564
| SMILES = NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CSSC4)CC(N)=O
}}
|Section2={{Chembox Properties
| Formula=C<sub>46</sub>H<sub>65</sub>N<sub>13</sub>O<sub>11</sub>S<sub>2</sub>
| MolarMass=1040.22 g/mol
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}

'''Felypressin''' is a non-[[catecholamine]] [[vasoconstrictor]] that is chemically related to [[vasopressin]], the posterior [[pituitary]] [[hormone]]. It is added to some [[local anaesthetic]]s such as [[prilocaine]] in a concentration of 0.03 IU/ml. Felypressin is a Vasopressin 1 agonist, and will thus have effects at all [[Arginine vasopressin receptor 1A]]s. It will, however, have its main physiological effects on vascular SMC's due to the form in which it is administered.

V1 receptors are found in various sites around the body.  The major points include the '''C'''NS, '''L'''iver, '''A'''nterior Pituitary, '''M'''uscle (both vascular and non-vascular smooth muscle), and '''P'''latelets (CLAMP).

Another example of a V1 agonist is [[terlipressin]] - which is used in [[oesophageal varices]].

==References==
{{Reflist|2}}
*"Vasopressin analogues and treatments", Prof Buckingham, Imperial College School of Medicine (ICSM) - adapted by JHPatel


{{Oxytocin and vasopressin receptor modulators}}

[[Category:Vasoconstrictors]]
[[Category:Peptides]]
[[Category:Vasopressin receptor agonists]]